Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Pantec Biosolutions reports first successful IVF pregnancy using P.L.E.A.S.E. –FSH patch

Ruggell, Liechtenstein, 8 February 2011- Pantec Biosolutions AG, a privately-owned company developing innovative transdermal drug delivery products, announced today that a woman has successfully conceived after being implanted with a fertilized oocyte (egg cell). The oocyte donor was treated with the company’s FSH (follicle stimulating hormone) patch subsequent to skin microporation with Pantec’s proprietary P.L.E.A.S.E.® (Painless Laser Epidermal System) device.

The CEO of Pantec, Dr. Christof Boehler, announced this news during a scientific presentation at the 16th Annual Drug Delivery Partnerships 2011 conference in Miami, Florida, USA. The pregnancy is the first to occur from a previously announced study in which follicular maturation was achieved using P.L.E.A.S.E. microporation and the FSH (IVF002) patch. Following the oocyte donation, the fertilized egg was transferred to the recipient, who subsequently became pregnant. The trial team was led by principal investigator, Dr. Petr Uher and medical expert, Professor Herbert Zech. The presentation can be downloaded here.

“We are very pleased that our treatment has helped a patient conceive and we wish her the best during her pregnancy,” said Christof Boehler, CEO of Pantec Biosolutions. “This is an extremely important milestone; not only for our company, but also for all women undergoing IVF treatments- it is a big step towards making the tedious IVF procedure more comfortable for all those hoping to get pregnant.”


About Pantec Biosolutions and P.L.E.A.S.E.®
Pantec Biosolutions AG is a private drug delivery company specialised in using laser microporation technology to deliver large molecular weight drugs into the epidermis for local or systemic uptake. Its proprietary P.L.E.A.S.E.® (Painless Laser Epidermal System) platform enables efficient, needle-free and painless administration of biopharmaceutical drugs, in varying and individualised dosages, through partnered patch technology. The technology is currently in clinical trials for the delivery of IVF hormone therapy, a market with an estimated value of US$1.5 – 2 billion.
Pantec Biosolutions’ P.L.E.A.S.E.® platform is available both for the development of the Company’s own pipeline and for penetration into new markets through strategic partnerships. Pantec Biosolutions is based in Ruggell, Liechtenstein.

Further Information:

Dr. Christof Boehler
Pantec Biosolutions AG
t: +423 377 7800

Dr. Robert Mayer
Senior Account Manager
College Hill Life Sciences
t: +49 (0)89 52 38 80 30

Notes for editors:
About FSH
Follicle-stimulating hormone (FSH) is a hormone found in humans and other animals. It is synthesized and secreted by gonadotropes of the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation, and reproductive processes of the body. FSH and Luteinizing hormone (LH) act synergistically in reproduction. FSH stimulates the growth and recruitment of immature ovarian follicles in the ovary.
Currently, FSH is self-administered by the patients for 10-12 days by daily subcutaneous or intramuscular injection stimulating follicle growth during an In Vitro Fertilisation (IVF) protocol. FSH is used in all major IVF procedures. The patch avoids these multiple injections thus improving ease of use and convenience.

Publisher Contact Information:

Pantec Biosolutions
+423 377 7800

Company profile of Pantec Biosolutions
Past press releases of Pantec Biosolutions.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 6€9.3MSoftware development
Dec 6€1.5MConsumer applications
Dec 6€3.7MInternet commerce
Dec 5€8.0MNanotechnology
Dec 5€11.0MBiotechnology
Dec 5€11.0MRobotics
Dec 5N/ARobotics

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.